Amgen Inc.
$249.48B- Market cap
- $204.01B
- Debt
- +$54.60B
- Cash
- −$9.13B
Capital structure 79% equity / 21% debt · EV / Revenue 6.79x · EV proxy / EBITDA proxy 17.51x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $204.01B · View financials
Snapshot Sep 11, 2026, 4:00 PM ET
FY 2025 ·
Decision snapshot: AMGN stock price near parity vs CHD $377.35 current versus $443.63 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CHD's multiple
Implied fair value · at AMGN's multiple
Snapshot Sep 11, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Multiple premium
Lower P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 79% equity / 21% debt · EV / Revenue 6.79x · EV proxy / EBITDA proxy 17.51x
Capital structure 91% equity / 9% debt · EV / Revenue 3.89x · EV proxy / EBITDA proxy 18.21x
AMGN carries the larger enterprise value at $249.48B against $24.13B; CHD trades on the lower EV / Revenue multiple (3.89x vs 6.79x); AMGN on the lower EV / EBITDA (17.51x vs 18.21x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Amgen Inc. · implied price per share
Bear
$121.60
Base
$161.79
Bull
$216.01
CHURCH & DWIGHT CO., INC. · implied price per share
Bear
$43.47
Base
$53.43
Bull
$66.87
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
REGENERON PHARMACEUTICALS, INC.
AMGN vs REGN
BIOGEN INC.
AMGN vs BIIB
VERTEX PHARMACEUTICALS INC / MA
AMGN vs VRTX
Gilead Sciences, Inc.
AMGN vs GILD
Moderna, Inc.
AMGN vs MRNA
Eli Lilly and Company
AMGN vs LLY
PROCTER & GAMBLE Co
AMGN vs PG
COLGATE PALMOLIVE CO
AMGN vs CL
KIMBERLY CLARK CORP
AMGN vs KMB
ESTEE LAUDER COMPANIES INC
AMGN vs EL
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe AMGN can sustain its 10.0% revenue growth and 43.5% ROIC without balance-sheet stress, then AMGN looks attractive versus CHD because it is cheaper on P/E and materially stronger on profitability.
AMGN trades at a lower P/E than CHD despite stronger operating metrics, while the implied price of $473.27 sits above both the current price and the top of the historical band. The valuation gap is supported more by earnings power than sales multiples, since AMGN looks richer on P/S but cheaper on P/E and EV/EBITDA.
Supporting Metrics